Supplementation of 2'-Fucosyllactose during the Growth Period Improves Neurodevelopmental Disorders in Offspring Mice Induced by Maternal Immune Activation.

Researchers studied a natural milk sugar called 2'-Fucosyllactose in young mice with autism-like behaviors. Giving this supplement daily for 5 weeks improved the mice's social behaviors and reduced brain inflammation. The supplement worked by improving gut health and increasing helpful bacteria. While promising, this early research in mice needs much more study before knowing if it could help autistic children.

This preclinical study investigated 2'-Fucosyllactose (2'-FL) supplementation in a mouse model of autism spectrum disorder induced by maternal immune activation. Three-week-old male mice received daily 2'-FL for 5 weeks. Results demonstrated significant improvements in autism-like behavioral deficits, restoration of intestinal barrier integrity, and increased beneficial gut bacteria associated with bile acid metabolism. The intervention elevated brain bile acid content and upregulated bile acid receptors.

Co-housing experiments confirmed gut microbiota's crucial role in mediating these benefits. The study suggests 2'-FL alleviates behavioral deficits and neuroinflammation through gut-brain axis regulation, though translation to humans requires further investigation.

While this preclinical research suggests 2'-Fucosyllactose may benefit autism symptoms through gut-brain axis modulation, significant additional research is needed before clinical application. Current evidence is insufficient to recommend this intervention for autistic individuals without proper human trials.

Animal model study with unclear sample size and unknown study duration details. Maternal immune activation model may not fully represent human autism etiology. Translation to human populations requires extensive additional research including safety and efficacy studies.

Autism spectrum disorder is a serious neurodevelopmental disorder whose early onset significantly affects an individual's social interactions and cognitive function. Recent research suggests that modulating the gut microbiota could be a potential intervention strategy for autism spectrum disorder symptoms. 2'-Fucosyllactose has been identified as a regulator of gut microbiota homeostasis, however, its effectiveness in addressing autism spectrum disorder remains unclear. In this study, the effects of daily supplementation of 2'-FL in 3-week-old male offspring mice for 5 weeks were examined. The results showed that 2'-fucosyllactose significantly improved autism spectrum disorder-like behavioral deficits.

Furthermore, supplementation with 2'-fucosyllactose restored intestinal barrier integrity and increased relative abundance of beneficial gut bacteria, particularlyandthat are closely related to bile acid metabolism. Notably, 2'-fucosyllactose treatment elevated the content of bile acids and upregulated the expression of bile acid receptors in the brain. Co-housing experiments further confirmed the crucial role of gut microbiota in mediating the beneficial effects of 2'-fucosyllactose. Overall, this study suggests that 2'-fucosyllactose could alleviate maternal immune activation-induced behavioral deficits and neuroinflammation through the regulation of the gut-brain axis, offering potential therapeutic value.